Search - tctmd.com

Displaying 1 - 3 of 3

Sort: Relevancy | Date

Full GALILEO Results Confirm Harm With Rivaroxaban After TAVR

News Conference News AHA 2019

Full GALILEO Results Confirm Harm With Rivaroxaban After TAVR

November 17, 2019

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

News Daily News

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Michael O'Riordan

August 26, 2019

RAS Inhibition After TAVR Gains More Support, but RCT Still Needed

News Daily News

RAS Inhibition After TAVR Gains More Support, but RCT Still Needed

July 29, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.